Brainstorm Cell Therapeutics Inc. (BCLI)
NASDAQ: BCLI · Real-Time Price · USD
2.230
+0.160 (7.73%)
At close: Dec 24, 2024, 12:59 PM
2.220
-0.010 (-0.45%)
After-hours: Dec 24, 2024, 1:49 PM EST
BCLI Employees
Brainstorm Cell Therapeutics had 29 employees as of December 31, 2023. The number of employees decreased by 14 or -32.56% compared to the previous year.
Employees
29
Change (1Y)
-14
Growth (1Y)
-32.56%
Revenue / Employee
n/a
Profits / Employee
-$490,621
Market Cap
12.72M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Lifeward | 108 |
STRATA Skin Sciences | 99 |
Aspira Women's Health | 64 |
Jaguar Health | 49 |
Apollomics | 45 |
AIM ImmunoTech | 28 |
Eterna Therapeutics | 8 |
Ensysce Biosciences | 7 |
BCLI News
- 16 days ago - BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update - PRNewsWire
- 22 days ago - BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology - PRNewsWire
- 23 days ago - BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024 - PRNewsWire
- 5 weeks ago - BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 6 weeks ago - BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing - PRNewsWire
- 2 months ago - BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - PRNewsWire
- 2 months ago - BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting - PRNewsWire
- 2 months ago - BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit - PRNewsWire